Promomed Group replenished its anti-cancer portfolio with a new drug product for prostate cancer

Abiraterone-Promomed used for the treatment of prostate cancer received marketing authorization certificate and became the second product in the anti-cancer portfolio of Promomed Group.

Prostate cancer remains one of the most relevant problems affecting the health of older men. Approaches to the treatment of this disease depend on the spread of tumor. Abiraterone-Promo media is a modern antiandrogenic drug used in the second line of hormone therapy for metastatic castration-resistant prostate cancer.

The formation of the drug product portfolio focused on the treatment of socially significant diseases including cancer is one of the most important tasks for the Promomed Group within the strategy to solve global medical problems, save lives and significantly improve the health of patients. When introducing new drugs to the market, including generics, the company offers patients effective and safe drug products through the high quality of substances, the technological effectiveness of production processes, and the highest quality control standards.

Abiraterone-Promomed will be available in tablets with a dosage of 250 mg corresponding to standard treatment regimens.

Like most drug products produced by Promomed Group, this drug is included in the list of vital and essential drugs.